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RESEARCH ARTICLE

Glycolysis upregulation is neuroprotective
as a compensatory mechanism in ALS
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Abstract Amyotrophic Lateral Sclerosis (ALS), is a fatal neurodegenerative disorder, with TDP43 inclusions as a major pathological hallmark. Using a Drosophila model of TDP-43 proteinopathy
we found significant alterations in glucose metabolism including increased pyruvate, suggesting
that modulating glycolysis may be neuroprotective. Indeed, a high sugar diet improves locomotor
and lifespan defects caused by TDP-43 proteinopathy in motor neurons or glia, but not muscle,
suggesting that metabolic dysregulation occurs in the nervous system. Overexpressing human
glucose transporter GLUT-3 in motor neurons mitigates TDP-43 dependent defects in synaptic
vesicle recycling and improves locomotion. Furthermore, PFK mRNA, a key indicator of glycolysis,
is upregulated in flies and patient derived iPSC motor neurons with TDP-43 pathology. Surprisingly,
PFK overexpression rescues TDP-43 induced locomotor deficits. These findings from multiple ALS
models show that mechanistically, glycolysis is upregulated in degenerating motor neurons as a
compensatory mechanism and suggest that increased glucose availability is protective.
DOI: https://doi.org/10.7554/eLife.45114.001
*For correspondence:
zarnescu@email.arizona.edu
Competing interests: The
authors declare that no
competing interests exist.
Funding: See page 16
Received: 12 January 2019
Accepted: 20 May 2019
Published: 10 June 2019
Reviewing editor: Harry T Orr,
University of Minnesota, United
States
Copyright Manzo et al. This
article is distributed under the
terms of the Creative Commons
Attribution License, which
permits unrestricted use and
redistribution provided that the
original author and source are
credited.

Introduction
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease affecting upper and lower motor
neurons resulting in progressive muscle weakness and eventual death (Hardiman et al., 2017). Cellular metabolic defects arise early, and contribute to the clinical manifestation of systemic defects
that include weight loss, dyslipidemia, and hypermetabolism (reviewed in Dupuis et al., 2011;
Joardar et al., 2017). However, it is unclear how metabolic defects relate, or may contribute to
motor neuron degeneration.
Observations from both patients and animal models have begun to elucidate the mechanisms
that contribute to metabolic defects in ALS. Interestingly, the human brain relies on glucose as its
major energy source, and consumes ~20% of the body’s glucose derived energy
(Mergenthaler et al., 2013). Glucose metabolism defects have been previously reported in the frontal lobe and the cortex of ALS patients (Ludolph et al., 1992), and in mutant SOD1 mouse models
of ALS (Browne et al., 2006; Miyazaki et al., 2012). Increasing glucose availability has been shown
to reduce protein misfolding and delay neuronal degeneration in C. elegans models of neurodegeneration (Tauffenberger et al., 2012). In a recent pilot study, a high caloric diet based on high carbohydrate content has been shown to be well tolerated by patients, and reduce serious adverse events
in ALS patients (Wills et al., 2014). Taken together, these findings suggest that although defective
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glucose metabolism is still poorly understood in ALS, there lies a great opportunity to better understand its relationship to disease and explore its potential as a therapeutic avenue.
Our lab has developed a Drosophila model of ALS based on overexpression of human TDP-43
that recapitulates multiple disease aspects including cytoplasmic aggregates, neuromuscular junction
(NMJ) abnormalities, lifespan, and locomotor defects (Estes et al., 2011; Estes et al., 2013). Importantly, the large majority of ALS patients (>97%) harbor TDP-43 cytoplasmic aggregates regardless
of etiology, highlighting the importance of understanding TDP-43 toxicity mechanisms (Ling et al.,
2013; Neumann et al., 2006). Here, we report that in a Drosophila model of TDP-43 proteinopathy,
glycolytic metabolites and genes are altered, and are consistent with increased glucose consumption. Moreover, key genes responsible for driving glucose metabolism are upregulated in both
patient derived induced pluripotent stem cell (iPSC) motor neurons and postmortem patient spinal
cord tissue. In a fly model of TDP-43 proteinopathy, increased dietary glucose improves locomotor
function and increases lifespan when TDP-43 is expressed in the central nervous system but not
muscles. Additionally, genetic over-expression of human glucose transporters improves locomotor
function, mitigates neuromuscular junction defects, and improves lifespan in a variant dependent
manner. Finally, motor neuron overexpression of PFK, the rate limiting enzyme in glycolysis,
improves locomotor function, suggesting that upregulation of glycolysis is neuroprotective through
a compensatory mechanism in ALS. Together, our results show that increased glucose availability
protects motor neurons and improves overall outcome in models of TDP-43 proteinopathy.

Results
Glycolysis and pentose phosphate pathways are altered by TDP-43
expression in motor neurons
To decipher metabolic alterations in ALS, we employed a Drosophila model of TDP-43 proteinopathy that recapitulates key features of the human disease including locomotor dysfunction and
reduced survival (Estes et al., 2011; Estes et al., 2013). We conducted metabolomic profiling in
whole third instar larvae expressing TDP-43 in motor neurons (D42 >TDP-43WT or D42 >TDP43G298S) and controls (D42>w1118). These experiments showed significantly increased phosphoenolpyruvate (PEP) and pyruvate in both TDP-43WT and TDP-43G298S suggesting an increase in glucose
metabolism (PEP, Pvalue = 0.034 and pyruvate, Pvalue = 0.007 for TDP-43WT; PEP, Pvalue = 0.002 and
pyruvate, Pvalue = 0.009 for TDP-43G298S; see Figure 1 and Supplementary file 1). Interestingly,
pyruvate does not appear increased when endogenous TDP-43 is knocked down by RNAi in motor
neurons suggesting that this alteration is caused by TDP-43 proteinopathy (Figure 1—figure supplement 1). In larvae expressing TDP-43G298S, we also found a decrease in ribulose/xylulose 5-phosphate (Pvalue = 0.011) in conjunction with increased sedoheptulose 7-phosphate (Pvalue = 0.008)
suggesting that increased glycolytic input into the Pentose Phosphate Pathway occurs in a variant
dependent manner (see Figure 1, Supplementary file 1). Taken together these findings suggest
that glucose metabolism is altered in the context of TDP-43 proteinopathy, consistent with previous
reports of metabolite alterations such as increased pyruvate in plasma isolated from ALS patients
(Lawton et al., 2012).

Key glycolysis and pentose phosphate pathway enzymes are
upregulated by TDP-43 expression in motor neurons
An increase in glycolytic metabolites suggests a possible increase in glycolysis. To test this hypothesis, we profiled the expression of multiple enzymes known to regulate flux through glycolysis and
the Pentose Phosphate Pathway. Phosphofructokinase-1 (PFK1; PFK in Drosophila) levels are considered to be rate-limiting and control the rate of glycolysis, thus PFK expression provides a reliable
determinant of flux for glucose breakdown (Tanner et al., 2018).
To measure the levels of PFK in the context of TDP-43 proteinopathy we performed qPCR in ventral nerve chords dissected from third instar larvae expressing TDP-43WT or TDP-43G298S in motor
neurons (D42 >TDP-43) and w1118 controls. These experiments showed that PFK transcript levels are
increased in the context of TDP-43WT or TDP-43G298S, albeit statistical significance was only achieved
in the mutant TDP-43 (37% increase, Pvalue = 0.06 for TDP-43WT and 59% increase, Pvalue = 0.014 for
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Figure 1. Glycolysis and pentose phosphate pathways are altered by TDP-43 expression in motor neurons. (A) Metabolite changes in glycolysis for
whole larvae expressing TDP-43WT or TDP-43G298S were analyzed using mass spectrometry (see Materials and methods). Green and red font represent
metabolites that are significantly changed compared to controls (w1118), as indicated. PEP and pyruvate were upregulated in both TDP-43WT and TDP43G298S expressing flies. Changes in the pentose phosphate pathway metabolites are specific to larvae expressing TDP-43G298S. (B, C, D) Significant
changes in select metabolites shown as box and whisker plots. Whiskers represent maximum and minimum values. Box edges represent upper and
lower quartiles. Median values are denoted by horizontal lines within each box. One-way ANOVA was used to identify metabolites that differed
significantly between experimental groups (N = 5).
DOI: https://doi.org/10.7554/eLife.45114.002
The following source data and figure supplements are available for figure 1:
Source data 1. Metabolic analysis.
DOI: https://doi.org/10.7554/eLife.45114.005
Figure supplement 1. Pyruvate measurements in whole larvae expressing RNAi knock-down constructs for the endogenous Drosophila TDP-43 (TBPH)
with the D42 GAL driver show no significant changes compared to w1118 controls.
DOI: https://doi.org/10.7554/eLife.45114.003
Figure supplement 1—source data 1. Pyruvate assay.
DOI: https://doi.org/10.7554/eLife.45114.004

TDP-43G298S; see Figure 2A). These results suggest that flux through glycolysis is significantly
increased in motor neurons in the context of TDP-43G298S.
Finally, glucose-6-phosphate dehydrogenase (G6PD; Zw in Drosophila) was selected due to its
role as the commitment step for the pentose phosphate pathway (PPP). Zw transcript levels are
increased specifically in TDP-43G298S (37% increase, Pvalue = 0.012, see Figure 2B) but not TDPWT,
consistent with increased glycolytic influx through the PPP in the context of mutant TDP-43.

PFK transcript is upregulated in human tissue
To confirm that the changes in our Drosophila model of ALS have clinical relevance, we assayed the
transcript levels of PFK in human tissues and patient derived iPSC motor neurons. Humans have
three isoforms of PFK, namely PFKM, PFKL, and PFKP. Although all are present in the brain, PFKL is
expressed at lower levels (Human Brain Transcriptome: http://hbatlas.org/) thus we focused on PFKP
and PFKM. For human tissues we used spinal cords isolated from ALS patients with TDP-43 proteinopathy and controls lacking neurological defects (see Supplementary file 2 for demographic information). qPCR experiments show that both PFKP and PFKM levels are significantly increased in
human spinal cords (PFKP: 80% increase, Pvalue <0.001; PFKM: 55% increase, Pvalue = 0.014,
Figure 2C). iPSC motor neurons were derived from a patient harboring the TDP-43G298S mutation
and differentiated as previously described (Coyne et al., 2017). qPCR profiling from iPSC derived
motor neurons differentiated for 69–77 days (three independent differentiations, see
Supplementary file 3) showed a 58% increase in PFKP (Pvalue = 0.010; see Figure 2D) and a 45%
increase in PFKM (Pvalue = 0.036). These experiments show that glycolysis is also upregulated in
patient spinal cords and motor neurons consistent with our findings in the fly model. Similarly, G6PD
transcript levels are increased by 49% in spinal cords of ALS patients (Pvalue = 0.015; see Figure 2C)
and by 52% in patient derived motor neurons (Pvalue = 0.012: see Figure 2D).
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Figure 2. Glycolytic enzymes are transcriptionally upregulated. qPCR profiling of PFK (A; N = 5) and G6PD (B;
N = 5) from ventral nerve cords of Drosophila. Human PFKP, PFKM, or G6PD mRNA levels were profiled in either
spinal cords (C; N = 8 control and 9 ALS cases) or human iPSCs (D; N = 3 differentiations). Kruskal-Wallis test was
used to identify significance.
DOI: https://doi.org/10.7554/eLife.45114.006
The following source data is available for figure 2:
Source data 1. Drosophila qPCR, ipsc neuron qPCR, and human spinal cord qPCR.
DOI: https://doi.org/10.7554/eLife.45114.007

TDP-43 proteinopathy alters the capacity of motor neurons to import
glucose
Our findings that TDP-43 expression in motor neurons alters glycolysis could be explained by an
effect on glucose flux. To evaluate the levels of glucose in motor neurons, in the context of TDP-43
proteinopathy, we used a genetically encoded, FRET based, glucose sensor, FLII12Pglu-700md6
(Fehr et al., 2003; Takanaga et al., 2008). The sensor comprises a bacterial glucose-sensing domain
and a pair of cyan and yellow fluorescent proteins that upon glucose binding, undergoes a conformational change and allows FRET to occur (Figure 3A). This genetically encoded sensor has been
previously used in conjunction with the GAL4-UAS system in Drosophila to detect glucose flux and
distribution in various cell types within the fly ventral nerve cord (Volkenhoff et al., 2018).
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Figure 3. TDP expressing neurons have altered capacity to import glucose. FRET based glucose sensor described in Volkenhoff et al. (2018) was
used to measure the glucose import capacity. Glucose sensor schematic described in (A). Ex – Excitation; Em – Emission. (B, C) TDP-43 expressing
neurons and controls were imaged to detect CFP and FRET signal. 12–14 neurons were imaged every 10 s for 20 min. Values shown are the mean of
12–14 individual cells (ROI) from two ventral nerve cords (B). Mean values for 5–10 min and 15–20 min time intervals were used to calculate the
‘baseline’ and ‘stimulated’ (‘Stim’) values respectively (C). Kruskal-Wallis test was used to calculate significance.
DOI: https://doi.org/10.7554/eLife.45114.008
The following source data and figure supplement are available for figure 3:
Source data 1. Glucose sensor data.
DOI: https://doi.org/10.7554/eLife.45114.010
Figure supplement 1. Raw images of glucose sensor (A) or glucose sensor in the context of TDP-43G298S (B).
DOI: https://doi.org/10.7554/eLife.45114.009

Upon stimulation with glucose, neurons expressing the glucose sensor alone or together with
TDP-43 showed a small but significant increase in the FRET/CFP ratio (Figure 3B,C). TDP-43WT
expressing neurons showed no significant difference in the FRET/CFP signal compared to controls
(Figure 3B,C, Pvalue <0.99). In contrast, TDP-43G298S expressing neurons showed a significant
increase in the FRET/CFP signal compared to controls (Figure 3B,C, Pvalue <0.001). These results
suggest that glucose flux is specifically enhanced in TDP-43G298S expressing neurons, and further
substantiate our findings that glycolysis and the pentose phosphate pathway are significantly
increased in the context of TDP-43 proteinopathy.
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A high glucose diet mitigates neuronal and glial induced TDP-43
toxicity
The alterations in glucose metabolism we have uncovered here could be a direct consequence of
TDP-43 proteinopathy, or alternatively, could reflect a coping mechanism. To distinguish between
these two scenarios, we fed TDP-43 expressing flies a high glucose diet. As we have previously
shown, the neuronal or glial expression of TDP-43WT or TDP-43G298S caused locomotor defects as
indicated by increased larval turning time compared to controls (Estes et al., 2011; Estes et al.,
2013). Of note, a high glucose diet increased the larval turning time of control larvae, consistent
with previous reports that high sugar intake induces insulin resistance and obesity in flies
(Musselman et al., 2011; Na et al., 2013). In contrast, a high glucose diet improved the larval locomotor defect caused by either neuronal, or glial expression of TDP-43 (Figure 4A and Figure 4—figure supplement 1). Interestingly, we found that increasing the concentration of glucose five-fold or
higher rescued locomotor phenotypes caused by TDP-43 while no improvement was observed when
glucose is only increased by two-fold (Figure 4—figure supplement 1). Next, we examined the
effect of glucose on lifespan and found that the reduced survival caused by neuronal or glial expression of TDP-43WT or TDP-43G298S was also significantly improved by feeding Drosophila a high sugar
(HS) versus a regular sugar (RS) diet (23.5 days for TDP-43WT on RF and 53 days for TDP-43WT on
HS, Pvalue<0.0001; 14.5 days for TDP-43G298S on RS and 41 days for TDP-43G298S HS, Pvalue<0.0001;
Figure 4B, Figure 4—figure supplement 2). Together, these results suggest that while a high sugar
diet is detrimental to control flies, it improves key hallmarks of motor neuron disease including locomotor dysfunction and reduced survival in ALS flies.

Overexpression of human glucose transporters mitigate TDP-43
dependent phenotypes in neurons or glia
Our results on a high sugar diet suggest that increased glucose availability is protective in our fly
model of ALS. However, because feeding can cause systemic effects, and to further probe the role
of glucose in our Drosophila model of ALS, we co-expressed TDP-43 and the human glucose transporter GLUT-3 in motor neurons or glia. GLUT-3 is the primary glucose transporter of mammalian
neurons, and has a high capacity for glucose (Ferreira et al., 2011). Co-expression of GLUT-3 and
TDP-43WT or TDP-43G298S, in either motor neurons or glia cells, improved the locomotor deficits
caused by TDP-43 expression alone (Figure 4C). Moreover, GLUT-3 expression in neurons improved
the locomotor ability of adult flies expressing TDP-43WT or TDP-43G298S (as measured by negative
geotaxis assays, Figure 4—figure supplement 3). When using the standard log-rank test for analyzing the survival data, lifespan was significantly increased when GLUT-3 was co-expressed with TDP43G298S in motor neurons, but not glial cells (18 days for TDP-43G298S and 30 days for TDP-43G298S,
Pvalue =<0.0001). However, when using the Mantel-Cox test, which weighs earlier deaths more significantly, we found that GLUT-3 overexpression increases lifespan when TDP-43G298S is expressed in
glial cells (43.5 days vs 51.5 days, Pvalue = 0.015). GLUT-3 had no effect on lifespan when TDP-43WT
was expressed in either motor neurons or glia. Importantly, GLUT-3 overexpression had no effect on
TDP-43 suggesting that its protective effect occurs through a mechanism independent of TDP-43
levels (see Figure 4—figure supplement 4). Together, these findings suggest that increased glucose
availability is protective in both motor neurons and glia but to a different extent that likely reflects
different metabolic capabilities of the two cell types.
Although GLUT-3 is the predominant glucose transporter in the brain, recently, the human glucose transporter GLUT-4, an insulin dependent glucose transporter expressed primarily in muscle
has been shown to localize to the plasma membrane to support synaptic activity (Ashrafi et al.,
2017). To test whether GLUT-4 also modulates TDP-43 proteinopathy, we co-expressed GLUT-4 and
TDP-43 in either motor neurons or glia. Similar to GLUT-3, co-overexpression of GLUT-4 and TDP43WT or TDP-43G298S, in either motor neurons or glial cells, improved the locomotor deficits caused
by TDP-43 expression alone (Figure 4—figure supplement 5). Notably, while TDP-43 overexpression in muscle causes larval turning phenotypes, co-overexpression of either GLUT-3 or GLUT-4 in
muscle does not mitigate TDP-43 dependent locomotor deficits, suggesting that the primary metabolic defect lies in the nervous system (Figure 4—figure supplements 2 and 5).
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Figure 4. A high glucose diet rescues neuronal TDP-43 toxicity in flies. TDP-43WT or ALS associated TDP-43G298S were expressed in MNs (using GAL4UAS). (A, B) Larval turning and lifespan assays for Drosophila fed a cornmeal based food containing either regular concentration of sugar (RS) or a high
sugar diet (HS:10x the standard amount of sugar). (C, D) Larval turning and lifespan assays for Drosophila expressing GLUT-3 on its own or with TDP-43,
as indicated. At least 30 larvae were tested in larval turning assays and on average 20 adults were assayed for survival. Kruskal-Wallis test and Log-rank
(Mantel-Cox) test was used to determine statistical significance for larval turning and survival curve respectively. * - p<0.05, ** - p<0.01, *** - p<0.001.
DOI: https://doi.org/10.7554/eLife.45114.011
The following source data and figure supplements are available for figure 4:
Source data 1. D4210x, 5x, 2x, 1x, 0x Glucose Larval Turning D42 AO; GLUT 3LT; GLUT3 survival; and HS survival.
DOI: https://doi.org/10.7554/eLife.45114.021
Figure supplement 1. Larval turning assays on regular cornmeal-molasses food supplemented with various amounts of glucose (2X, 5X or 10X, as
shown).
DOI: https://doi.org/10.7554/eLife.45114.012
Figure supplement 1—source data 1. Glucose Larval Turning.
DOI: https://doi.org/10.7554/eLife.45114.013
Figure supplement 2. A high sugar diet or GLUT-3 overexpression are partially protective when TDP-43 is expressed in glia but not in muscles.
DOI: https://doi.org/10.7554/eLife.45114.014
Figure supplement 2—source data 1. (i) Glia HS LT; (ii) Glia HS SC; (iii) Glia Glut3 LT; (iv) GLUT3 Glia SC; (v) Muscle HS LT; (vi) Muscle Glut3 LT.
DOI: https://doi.org/10.7554/eLife.45114.015
Figure supplement 3. Negative geotaxis assay on adult flies expressing TDP-43WT or TDP-43G298S alone or in conjunction with GLUT-3.
DOI: https://doi.org/10.7554/eLife.45114.016
Figure supplement 4. GLUT-4 overexpression mitigates locomotor defects when TDP-43 is expressed in motor neurons or glia but not muscles.
DOI: https://doi.org/10.7554/eLife.45114.017
Figure supplement 4—source data 1. Western Blot Quantifications.
DOI: https://doi.org/10.7554/eLife.45114.018
Figure supplement 5. Larval turning assays for GLUT-4 and TDP-43 overexpression in motor neurons (i), glia (ii) or muscles (iii).
DOI: https://doi.org/10.7554/eLife.45114.019
Figure supplement 5—source data 1. GLUT 4 Glia LT; GLUT4 MN LT; and GLUT4 Muscle LT.
Figure 4 continued on next page
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Figure 4 continued
DOI: https://doi.org/10.7554/eLife.45114.020

TDP-43 dependent defects at the neuromuscular junction are rescued
by GLUT-3
We previously described defects at the Drosophila neuromuscular junction (NMJ) caused by neuronal expression of TDP-43. These defects include a reduction in synaptic bouton number
(Coyne et al., 2014; Estes et al., 2013) and a reduction in synaptic vesicle endocytosis as indicated
by FM1-43 dye uptake experiments (Coyne et al., 2017). To test whether increased GLUT-3 could
also rescue morphological and functional defects at the larval NMJ, we co-expressed GLUT-3 and
TDP-43 in motor neurons. Co-expression of GLUT-3 rescued NMJ size as indicated by the total number of synaptic boutons in both TDP-43WT (Pvalue = 0.004) and TDP-43G298S (Pvalue = 0.023) expressing larvae (Figure 5A and C). Moreover, GLUT-3 overexpression partially restores synaptic vesicle
endocytosis deficits caused by TDP-43 (Figure 5B and D, Pvalue <0.001 for both TDP-43WT and TDP43G298S). Taken together, these results show that GLUT-3 expression in motor neurons mitigates
morphological and functional defects caused by TDP-43 at the NMJ and suggest that increased glucose availability in motor neurons is neuroprotective in ALS.

Neuronal co-expression of PFK rescues TDP-43 induced toxicity
Increased PFK levels in conjunction with our findings that increased glucose availability is protective
suggest that increased glycolysis may be compensatory. To test this hypothesis, we directly manipulated glycolysis genetically, either via PFK overexpression or RNAi knock-down, in the context of
TDP-43 proteinopathy. Overexpression of PFK alone in motor neurons negatively altered locomotor
activity suggesting that in normal neurons high glycolytic activity may be toxic (Figure 6A). However,
the co-expression of PFK with TDP-43WT or TDP-43G298S rescued locomotor defects to control levels
(Pvalue = 0.003 for TDP-43WT and Pvalue <0.001 for TDP-43G298S, Figure 6A). In contrast, PFK RNAi
knock-down had no significant effect on larval turning when expressed in motor neurons alone (53%
knock-down, Pvalue = 0.04, see Materials and methods). However, when PFK was knocked down by
RNAi in the context of TDP-43 proteinopathy we found that it significantly increased larval turning
times for TDP-43WT albeit it had no effect on TDP-43G298S (Pvalue <0.001 for TDP-43WT and
Pvalue = 0.767 for TDP-43G298S, Figure 6B). One possible interpretation for this variant dependent
effect is that the metabolic deficit of TDP-43G298S is so severe that it may be difficult to exacerbate
by further altering energy metabolism. Of note, a second PFK RNAi line (y(1) sc[*] v(1) P{y[+t7.7] v
[+t1.8]=TRiP.HMS01324}attP2) was tested, but was lethal when expressed in motor neurons.
Similar to the experiments with motor neurons, the over-expression of PFK in glial cells causes a
locomotor defect, while the expression of two independent PFK RNAi lines has no effect on locomotor activity as determined by larval turning assays (Figure 6—figure supplement 1). When PFK is
co-expressed in glial cells with TDP-43WT there is a slight but not statistically significant reduction in
larval turning (Pvalue >0.302) while it significantly mitigates TDP-43G298S (Pvalue = 0.001, Figure 6—
figure supplement 1). Moreover, the knockdown of PFK in conjunction with TDP-43WT significantly
impaired locomotor function when compared to TDP-43WT expression alone (Pvalue <0.001, Figure 6—figure supplement 1). PFK knock down did not affect TDP-43G298S expressing flies
Pvalue >0.057, Figure 6—figure supplement 1). Importantly, the protective effect of PFK overexpression in motor neurons does not occur via reducing TDP-43 levels (Figure 6—figure supplement
1). These results indicate that an increase in glycolysis, in either motor neurons or glial cells, can
ameliorate TDP-43 toxicity.

Compensatory upregulation of PFK transcript is not a consequence of
sequestration in TDP-43 insoluble complexes
Our findings of increased PFK mRNA levels and genetic interaction data with PFK support a protective compensatory mechanism (see Figure 7 for model). This could be in part explained by the ribostasis hypothesis (Ramaswami et al., 2013) whereby PFK mRNA associates with TDP-43 in insoluble
complexes and as a result, transcription is upregulated to compensate for the amount of mRNA
sequestered and unavailable for translation. This however, does not seem to be the case, as soluble
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Figure 5. TDP-43 dependent defects at the NMJ are rescued by GLUT-3. Third instar larvae NMJ from segment A3, muscle 6/7 were immunostained
for CSP and HRP (A) or analyzed for their ability to endocytose FM1-43 dye upon stimulation with 90 mM KCl (B). (A, C) Neuronal TDP-43 expression in
Drosophila neurons reduces the number of boutons (labeled with CSP and HRP (A, C) and reduces FM1-43 dye uptake (B, D). These morphological (A,
C) and functional (B, D) deficits are rescued by co-expression of GLUT-3. N = 7–10 larvae. Kruskal-Wallis test was used to identify significance.
DOI: https://doi.org/10.7554/eLife.45114.022
The following source data is available for figure 5:
Source data 1. Bouton count analysis and FM1-43 GLUT-3 analysis.
DOI: https://doi.org/10.7554/eLife.45114.023
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versus insoluble fractionation experiments do not support this hypothesis (Figure 7—figure supplement 1). Surprisingly, PFK mRNA appears to be more soluble in the context of TDP-43WT versus
TDP-43G298S, consistent with different TDP-43 variants utilizing distinct pathomechanisms, as we
have previously reported (Coyne et al., 2017; Estes et al., 2013).

Discussion
It is widely known that ALS patients display gross metabolic dysregulation described as hypermetabolism (for a recent review, see Joardar et al., 2017). However, a major challenge in the field has
been to understand how these clinical observations relate to metabolic changes at the cellular level.
Here, we take advantage of cell type specific genetic tools available in Drosophila to pinpoint how
specific metabolic changes in neurons and glia relate to disease progression. Using metabolic profiling we first found that the neuronal expression of TDP-43 increases the abundance of pyruvate, the
end product of glycolysis. Notably, this alteration is consistent with metabolite changes in plasma
from ALS patients (Lawton et al., 2012) and suggest an increase in glycolysis. Substantiating this
scenario is transcriptional profiling of ALS spinal cords and patient derived iPSC motor neurons
showing that just as in flies, PFK, the rate limiting step in glycolysis, is significantly upregulated (Figure 2). Interestingly, metabolic profiling in flies also suggests increased glycolytic input into the pentose phosphate pathway (Supplementary file 1), which provides a mechanism for countering
oxidative stress via increased NADPH production (Kruger and von Schaewen, 2003). Supporting
this possibility are our findings that G6PD, the rate limiting enzyme of the pentose phosphate pathway is upregulated in fly and human ALS ventral and spinal cords, respectively (Figure 2). Oxidative
stress is a well-established ALS manifestation (Barber and Shaw, 2010) and the most recent FDA

Figure 6. Co-overexpression of PFK rescues TDP-43 induced locomotor defects. (A) TDP-43WT or ALS associated TDP-43G298S were expressed in MNs
(using the GAL4-UAS system together with Drosophila UAS-PFK). (B) TDP-43WT or ALS associated TDP-43G298S were expressed in MNs (using the GAL4UAS system together with Drosophila UAS-PFKRNAi). N = 30 larvae. Kruskal-Wallis was used to determine statistical significance. * - P value < 0.05, ** - P
value < 0.01, *** - P value < 0.001.
DOI: https://doi.org/10.7554/eLife.45114.024
The following source data and figure supplements are available for figure 6:
Source data 1. PFK D42 LT.
DOI: https://doi.org/10.7554/eLife.45114.027
Figure supplement 1. Larval turning assays for PFK overexpression (i) or RNAi (ii) in the context of TDP-43 in glia.
DOI: https://doi.org/10.7554/eLife.45114.025
Figure supplement 1—source data 1. PFK Glia.
DOI: https://doi.org/10.7554/eLife.45114.026
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approved drug for treating ALS patients, Radicava, is aimed at countering this aspect of the disease
(Cruz, 2018). Collectively, molecular and metabolic alterations identified in the fly validate in patient
derived motor neurons and spinal cords, albeit the magnitude of the changes found in human ALS
tissues is often more dramatic and, at some level, more comparable with mutant TDP-43 dependent
phenotypes in flies. These findings highlight the predictive power of the fly model and its relevance
to studying disease pathomechanisms in humans.
Using a genetically encoded glucose sensor we show that TDP-43G298S expressing motor neurons
have increased capacity to import glucose (Figure 3). This is consistent with increased glycolysis and
its end product, pyruvate. It is unclear why despite finding that pyruvate is also increased in motor
neurons overexpressing TDP-43WT, we could not detect higher glucose uptake than in controls,
although this is consistent with PFK transcript levels trending up, yet not reaching significance in our
data set (Figure 2). A possible explanation is that while our model is based on TDP-43 expression
specifically in motor neurons or glia, the metabolite profiling was performed on whole larvae and
captured non-cell autonomous changes, occurring in cells other than motor neurons. Nevertheless,
taken together our data show that there is a clear dysregulation of glycolysis in TDP-43 expressing
Drosophila and patient tissue samples. Alterations in glucose metabolism may also be a feature of
multiple ALS types. Indeed, pre-symptomatic SOD1 mutant mice have been shown to have high glucose levels in spinal cords; however, glucose levels gradually decrease as disease symptoms progress (Miyazaki et al., 2012). One question that remained is whether alterations in glucose
metabolism are compensatory or causative.
In an effort to address this question, we first increased glucose availability in Drosophila by raising
the dietary concentration of glucose (5–10 X higher than normal levels in standard fly food), which
mitigates locomotor defects and increases lifespan in ALS flies while making wild-type larvae sluggish (Figure 3). Interestingly, a high sugar diet only mitigates locomotor defects when TDP-43 is
expressed in motor neurons or glia but not muscles, indicating that the primary metabolic defect lies
in the nervous system and that muscles do not benefit from increased glucose availability (Figure 4
and Figure 4—figure supplements 2 and 5). This is somewhat surprising given that muscles normally rely on glycolysis for ATP production but is also consistent with findings that in ALS, muscles
switch to primarily using lipids and not glucose for energy production (Palamiuc et al., 2015).
This systemic approach, however, does not provide information on which cells specifically benefit
from increased glucose availability. To answer this question, we intervened genetically by overexpressing human glucose transporters GLUT-3 or GLUT-4 in motor neurons, glia or muscles (Figures 4
and 5 and Figure 4—figure supplements 2 and 5). These experiments showed that both GLUT-3

Figure 7. Proposed model showing PFK transcript levels increase in response to TDP-43 proteinopathy. (A)
Neurons from non-diseased patients. (B) ALS neurons showing an increase in PFK transcript levels. SV – synaptic
vesicle.
DOI: https://doi.org/10.7554/eLife.45114.028
The following source data and figure supplements are available for figure 7:
Figure supplement 1. Cellular fractionations from third instar larvae.
DOI: https://doi.org/10.7554/eLife.45114.029
Figure supplement 1—source data 1. Soluble fractionations.
DOI: https://doi.org/10.7554/eLife.45114.030
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and GLUT-4 rescued locomotor dysfunction of TDP-43 expressing larvae in the nervous system, but
not in muscles (Figure 4 and Figure 4—figure supplements 2 and 5) confirming our findings from
high sugar feedings. Furthermore, our findings that overexpression of either GLUT-3 or GLUT-4 can
help mitigate specific ALS-like phenotypes in flies are consistent with recent reports that both GLUT3 and GLUT-4 are required at synapses to regulate activity (Ashrafi et al., 2017; Ferreira et al.,
2011). Together, our dietary intervention and GLUT-3/4 overexpression experiments indicate that
increased glucose availability in motor neurons and glia confers protection in models of TDP-43 proteinopathy, in a cell type dependent manner.
A possible explanation for why increased glucose availability improves defects caused by TDP-43
proteinopathy is that cells are actively consuming glucose to increase glycolytic flux. A recent study
using vertebrate cell lines suggests that glycolytic flux depends on four key steps. They include: (1)
glucose uptake by glucose transporters, (2) hexokinase levels, (3) PFK levels (and associated
enzymes), and (4) lactate export, but not other enzymes or steps involved in glycolysis
(Tanner et al., 2018). The co-over-expression of PFK mitigates TDP-43 defects in flies, and is consistent with our GLUT-3 over-expression experiments (Figure 6). Surprisingly, PFK transcript levels
were higher in human ALS post-mortem tissues compared to controls, however protein levels in total
tissue homogenates were not significantly increased despite trending upwards (data not shown).
Nevertheless, our findings of increased PFK mRNA levels in flies and human tissues, and the genetic
interaction experiments support the notion that glycolysis is increased in ALS as a compensatory
mechanism (see Figure 7 for model).
The fact that neurons would compensate deficits in cellular energetics through increasing glycolysis makes sense in the light of well-established defects in mitochondrial function. TDP-43 has been
previously shown to localize to the inner mitochondrial membrane of mitochondria (Wang et al.,
2016), and it has been shown to cause abnormally small mitochondria in Drosophila (Khalil et al.,
2017). Consistent with the importance of glycolysis in neurodegeneration, there are reports of SNPs
within PFK that are present in ALS patients but not in healthy controls (Rouillard et al., 2016;
Xie et al., 2014). Our findings that glycolysis is increased as a compensatory mechanism and this
confers neuroprotection is consistent with findings from a small clinical trial showing that a high caloric high carbohydrate diet improves patient outcome (Wills et al., 2014) and also that patients with
diabetes have a later onset of disease (Kioumourtzoglou et al., 2015). While upregulation of glycolysis decreases the dependence of the organism for ATP derived from mitochondria, it is also possible that increased glycolysis is improving organismal health through a different mechanism. For
example, pyruvate has been previously shown to protect mitochondria from oxidative stress
(Wang et al., 2007). Future studies should focus on the link between glycolysis, oxidative stress and
mitochondria in ALS.

Materials and methods
Key resources table
Reagent type
(species) or
resource

Designation

Source or
reference

Identifiers

Additional information

Genetic
reagent
(D. melanogaster)

w1118;UAS;TDPWTYFP

doi:
10.1242/dmm.
010710

TDPWT

Stock maintained
by the Zarnescu
Laboratory

Genetic
reagent
(D. melanogaster)

w1118;UAS-TDPG298SYFP

doi:
10.1242/dmm.
010710

TDPG298S

Stock maintained
by the Zarnescu
Laboratory

Genetic
reagent
(D. melanogaster)

w1118;UAS-GLUT-3

doi:
10.1371/journal.
pone.0118765

GLUT-3

Stock maintained
by the Liévens
Laboratory

Genetic
reagent
(D. melanogaster)

UAS-HA-GLUT-4-GFP

doi:
10.1371/journal.
pone.0077953

GLUT-4

Stock maintained
by the Pick
Laboratory

Continued on next page
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Continued
Reagent type
(species) or
resource

Designation

Source or
reference

Identifiers

Additional information

Genetic
reagent
(D. melanogaster)

UAS-FLII12Pglu700md6

doi:
10.1016/j.jinsphys.
2017.07.010

Glucose Sensor

Stock maintained
by the Schirmeier
Laboratory

Genetic
reagent
(D. melanogaster)

Motor neuron - D42GAL4 Driver

Bloomington

FBst0008816

Genetic
reagent
(D. melanogaster)

Repo- Glial GAL4
driver

Bloomington

FBti0018692

Genetic
reagent
(D. melanogaster)

Bg487 - Muscle
driver

Bloomington

FBti0004407

Genetic
reagent
(D. melanogaster)

TBPH RNAi

Bloomington

FBst0039014

Genetic
reagent
(D. melanogaster)

TBPH RNAi

Bloomington

FBti0128633

Genetic
reagent
(D. melanogaster)

PFK over
expression

Bloomington

FBst0060675

genetic
reagent
(D. melanogaster)

PFK RNAi

Bloomington

FBst0034336

genetic
reagent
(D. melanogaster)

PFK RNAi

Bloomington

FBst0036782

Used as second
RNAi line for glial
expression

Antibody

DCSP-2

DSHB

6D6

1/300

Antibody

Alexa Fluor 488
Phalloidin

ThermoFisher

A12379

1/200

Antibody

Alexa Fluor 568

Invitrogen

A10037

1/500

Antibody

Anti-HRP -CY5

Jackson Labs

123-165-021

1/200

Antibody

GFP Monoclonal

Takara

6326375

1/20000

Antibody

GFP Polyclonal

ThermoFisher

A-11122

1/1000

Antibody

b-Actin

Cell Signaling

4967

1/1000
1/1000

Antibody

b-Tubulin

Millipore Sigma

Mab3408

Commercial
assay or kit

Pyruvate Assay Kit

abcam

ab65342

Chemical
compound

FM 1–43 Dye

ThermoFisher

T3163

Other

Primer: Human
Phosphofructokinase
P (PFKP)

ThermoFisher

Assay ID
Hs00242993_m1

Other

Primer: Human
Phosphofructokinase
M (PFKM)

ThermoFisher

Assay ID
Hs00175997_m1

Other

Primer: Human G6PD

ThermoFisher

Assay ID
Hs00166169_m1

Other

Primer: Human
GAPDH

ThermoFisher

Assay ID
Hs99999905_m1
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Drosophila genetics
Standard crosses were incubated at 25˚C with a 12 hr alternating dark-light cycles. (i) w1118 (ii) w1118;
UAS-TDP43WT-YFP (iii) w1118; UAS-TDP43G29S8-YFP (iv) UAS-GLUT3 flies were crossed with the
GAL4 motor neuron driver D42. GLUT3 TDP-43 recombinant flies were generated using standard
genetic techniques. GLUT3 flies were described in Besson et al. (2015).
TDP-43 was expressed in motor neurons and glia using the D42 GAL4 (Gustafson and Boulianne,
1996) and repo GAL4 (Sepp et al., 2001) drivers, respectively. w1118 was crossed with either the
D42 or repo GAL4 drivers as a control. Endogenous TDP-43 was knocked down via RNAi using y[1] v
[1]; P{y[+t7.7] v[+t1.8]=TRiP.HMS01932}attP40 and y[1] v[1]; P{y[+t7.7] v[+t1.8]=TRiP.HM05194}
attP2.
To manipulate PFK, we used w1118; P{w[+mC]=UAS Pfk.T}3 for over expression, and y1 sc* v1; P{y
[+t7.7] v[+t1.8]=TRiP.HMS01324}attP2 or y1 sc* v1; P{y[+t7.7] v[+t1.8]=TRiP .GL00298}attP2 (Line 2,
viable only in glial expressing flies) for PFK knock down. attP2 was used as a genetic background
control for PFK RNAi knock-down experiments. All lines were obtained from the Bloomington Stock
Center.
PFK RNAi efficiency was assayed by crossing PFK RNAi to D42 GAL4. Ventral nerve cords were
dissected and analyzed via qPCR (see below for primers). A Welch’s t-test was used to identify
significance.

Fly food supplementation
Standard yeast/cornmeal/molasses food was heated and then allowed to cool to 55–60˚C. For high
sugar supplementation, additional glucose was added to reach a final concentration of 357 g/L (10X
compared to regular food). Supplemented food was dispensed into vials and allowed to cool.

Locomotor assays
Larval turning assays were performed as previously described (Estes et al., 2011; Estes et al.,
2013). Briefly, larvae are placed on a petri dish filled with solidified agar (2.5%) and grape juice.
Third instar larvae are transferred from a vial onto the agar/juice surface and are allowed to acclimate. Using a clean paintbrush, larvae are turned ventral side up. The time it takes for larvae to turn
themselves ventral side down and make a forward motion is recorded. Larval turning data were analyzed using Kruskal-Wallis multiple comparison tests (GraphPad Prism v8). Negative geotaxis assays
on adult flies were performed by using TDP-43 expressing flies with a milder phenotype/lethality.
TDP-43WT and TDP-43G298S flies were previously described in Khalil et al. (2017). Briefly, TDP-43
and GLUT-3 were expressed in neurons with the pan neuronal driver, elav GAL4. Female flies of 11
day old were anesthetized with CO2 and placed in a plastic column (diameter 1.3 cm) with a mark at
22 cm. After 20 min recovery, flies were gently tapped to the bottom of the column. Then the percentages of flies reaching the 22 cm mark or remaining at the bottom were counted after 60 s. The
test was repeated three times and results were averaged. The data are the mean of at least six trials
and are expressed as mean ± SEM. Statistical comparisons were performed using one-way ANOVA
followed by Tukey’s multiple-comparison test.

Metabolite analysis
Metabolomic analysis was conducted by Metabolon, Inc as previously described (Joardar et al.,
2015; Manzo et al., 2018). Briefly, 50–60 wandering third instar larvae (~50–60 mg) per sample
were collected and flash-frozen in liquid nitrogen. A total of 5 replicates per genotype were collected. Samples were analyzed by ultrahigh performance liquid chromatography/mass spectrometry
(UHPLC/MS), or by gas chromatography/mass spectrometry (GC/MS). One-way ANOVA was used to
identify biochemicals that differed significantly between experimental groups.

Pyruvate measurements
Pyruvate was measured using the Pyruvate Assay Kit (Abcam-ab65342) as per manufacturer’s instructions. In brief, 20 3rd instar larvae per genotype were analyzed in three biological replicates. Standard curve was generated kit provided reagents. Results are shown (Figure 1—figure supplement
1) in nmoles/microliter.

Manzo et al. eLife 2019;8:e45114. DOI: https://doi.org/10.7554/eLife.45114

14 of 20

Research article

Neuroscience

RNA isolation, cDNA preparation and qPCR cDNA protocol has been previously described
(Manzo et al., 2018). Briefly, five ventral nerve cords (VNCs) were isolated from third instar larvae
per genotype using HL-3 saline buffer (70 mM NaCL, 5 mM KCl, 22 mM MgCl2, 10 mM NaHCO3, 5
mM trehalose, 115 mM sucrose, 5 mM HEPES, pH 7.3). RNA was extracted using the RNeasy RNA
Extraction Kit (Qiagen) and stored at 80˚C. Genomic DNA (gDNA) was cleared using a DNase I
(Thermo Fisher Scientific) digestion protocol. Following gDNA clearing, reverse transcription was
performed using the Maxima First Strand cDNA Synthesis Kit for RT-qPCR (Thermo Fisher Scientific).
The quality of the cDNA was tested using GPDH primers (see below for sequence) and GoTaq endpoint polymerase chain reaction (PCR) protocol (Promega). Quantitative PCR was performed using a
SYBR Green protocol (Applied Biosystems) and primers designed to span exon-exon junctions. Each
reaction was conducted in 3–6 biological replicates with three technical replicates each. DDCT values
are normalized to GPDH (Pfaffl, 2001).The Kruskal-Wallis test was used to assess statistical significance in GraphPad Prism v8. Protocols for human tissue RNA isolation and cDNA preparation have
been previously described (Bakkar et al., 2018). RT-PCR was performed using TaqMan Gene
Expression Assays following the TaqMan Fast Advanced Master Mix protocol (Applied Biosystems)
on the QuantStudio 6 Flex instrument (Applied Biosystems).

Primer sequences and taqman probes
Drosophila Phosphofructokinase (PFK): Forward primer - TGGACGAGCTGGTCAAGAAC; Reverse
primer - CCACAAGAGCTAAATAGCCG
Drosophila G6PD (Zw): Forward primer - AAGCGCCGCAACTCTTTG; Reverse primer AGGGCGGTGTGATCTTCC
Drosophila GPDH: Forward primer - CCGCAGTGCTTGTTTTGCT; Reverse primer – TA
TGGCCGAACCCCAGTTG
Human Phosphofructokinase P (PFKP): Assay ID Hs00242993_m1
Human Phosphofructokinase M (PFKM): Assay ID Hs00175997_m1
Human G6PD: Assay ID Hs00166169_m1
Human GAPDH: Assay ID Hs99999905_m1

Glucose sensor
Third instar larval brains where dissected in HL3-buffer (70 mM NaCl, 5 mM KCl, 20 mM MgCl2, 10
mM NaHCO3, 115 mM sucrose, 5 mM trehalose, 5 mM HEPES; pH 7.1). Of note, the glucose sensor
is not sensitive to trehalose (Volkenhoff et al., 2018). Larvae were pinned down on a Sylgard plate
using insect pins and cleaned so that the ventral nerve cord is clearly visible. A 40x water immersion
lens was used to image larvae individually. For glucose stimulation, HL3-buffer was removed and
replaced with 5 mM glucose supplemented HL3 (70 mM NaCl, 5 mM KCl, 20 mM MgCl2, 10 mM
NaHCO3, 115 mM sucrose, 5 mM glucose, 5 mM HEPES, pH 7.1).
Fluorescent images were acquired using a Zeiss LSM880 NLO upright multiphoton/confocal
microscope. CFP was excited using a 405 nm laser, and images were acquired in both the CFP (CFP
465–499 nm) and the FRET (535–695 nm) detection channels.
Data was analyzed using ImageJ with a drift correction plugin turboreg (Thévenaz et al., 1998).
Regions of interest (ROIs) were manually selected and the mean grey value of each ROI was
extracted. The mean grey values for the FRET and CFP channels was taken to calculate the FRET
ratio (F/C), which corresponds to the intracellular glucose concentration.
Each ROI was imaged every 10 s for 10 min (baseline) and then for another 10 min under high glucose HL-3 (stim; see Figure 3—figure supplement 1 for representative examples). Each FRET ratio
was normalized to the mean baseline value for each genotype. For baseline vs stim comparisons
(Figure 3B), the normalized FRET ratio of each ROI was taken from minutes 5–10 and minutes 15–
20.

Western blots
TDP-43 was detected via its YFP tag using either the Clontech/Takara Living Colors GFP monoclonal
antibody (6326375) at 1:1000 (for Figure 4—figure supplement 4) or the ThermoFisher polyclonal
antibody (A-11122) at 1:1000 (for Figure 6—figure supplement 1). For normalization we used either
the Cell Signaling polyclonal rabbit anti b-Actin antibody (4967) at a 1:1000 dilution or the Millipore
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Sigma monoclonal antibody against beta tubulin (Mab3408) at 1:1000. 5% milk was used as blocking
agent for all westerns.

FM1-43 experiments
Larvae are dissected in HL-3 buffer on a sylgard dish as previously described. FM1-43 dye uptake
assays were conducted using 4 mM FM1-43FX, 90 mM KCl, and 2 mM Ca2+ for stimulation. Methods
adapted from Kuromi and Kidokoro (2005) and Verstreken et al. (2008). To determine dye uptake
signal, the background-corrected fluorescence for every synaptic bouton was calculated by subtracting the mean background fluorescence of cell-free regions equal in size to the synaptic bouton.

Bouton counts
Larval NMJs were dissected and fixed with 3.5% paraformaldehyde in PBS (pH 7.2: 130 mM NaCl, 5
mM Na2HPO4, 5 mM NaH2PO4) for 30 min. Antibody dilutions are as follows: 1:300 mouse antiDCSP2 (DSHB), 1:500 anti-mouse Alexa Fluor 568 (Invitrogen), 1:200 Anti-HRP-CY5 conjugate (Invitrogen), and 1:40 Phalloidin-488 (Invitrogen). Blocking solution contained 2% BSA and 5% Normal
goat serum. Methods have been previously described in Coyne et al. (2014).
Larval muscles 6 and 7, segment A3, were imaged using an LSM 880 confocal microscope (Zeiss).
NIH ImageJ was used to count bouton numbers and measure muscle area. Bouton count was normalized to muscle area to account for size variation.

iPSC methods
Control iPSC and TDP-43 iPSC cells were differentiated to motor neurons as previously described
(Donnelly et al., 2013; Zhang et al., 2016).

Cellular fractionations
To generate cellular fractions, 25 Third instar wandering larvae were flash frozen, followed by
homogenization in Trizolreagent using the Bullet Blender Bead Lysis Kit Green in conjunction with a
Bullet Blender Blue 24. Homogenates were then centrifuged at 2000 x g for 3 min. The supernatant
was separated from both the fat layer and the beads then it was further centrifuged at 25,000 g for
30 min. The resulting supernatant is the soluble fraction and the insoluble fraction is generated by
resuspending the pellet in urea buffer (30 mM Tris, 7 M Urea, 2 M Thiourea, 4% CHAPS, 1X Protease
Inhibitor Cocktail (Roche), 0.5 mM PMSF, 40 units/ml RNAsin plus, pH 8.5). RNA was isolated from
inputs and the cellular fractions utilizing the manufactured described protocol for Trizol reagent.
cDNA was then generated utilizing Thermoscientific Maxima First Strand cDNA Synthesis Kit for RTqPCR. RT-qPCR was conducted on the StepOnePlus RT-qPCR machine utilizing Sybr reagents.

Statistics
All statistical analyses for locomotor assays or qPCR comprising three or more data sets were conducted using Kruskal-Wallis with uncorrected Dunn’s test in Prism v8.0 (GraphPad). When only two
data sets were compared, either Welch’s test or Wilcoxon signed-rank test were used. Biological
replicates for qPCR and metabolomics are defined as independent sample collections per genotype,
from independent genetic crosses. All qPCR experiments included three technical replicates per biological replicate. Outliers were removed using ROUT method (Q = 1%) in Prism v8.0.
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Thévenaz P, Ruttimann UE, Unser M. 1998. A pyramid approach to subpixel registration based on intensity. IEEE
Transactions on Image Processing 7:27–41. DOI: https://doi.org/10.1109/83.650848, PMID: 18267377
Verstreken P, Ohyama T, Bellen HJ. 2008. FM 1-43 labeling of synaptic vesicle pools at the Drosophila
neuromuscular junction. Methods in Molecular Biology 440:349–369. DOI: https://doi.org/10.1007/978-159745-178-9_26, PMID: 18369958
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